March 2021 tender notification
PHARMAC is pleased to provide the latest tender results.
Tender results
PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply Status, Hospital Supply Status (as relevant) commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 April 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Levonorgestrel |
Tab 1.5 mg; 1 tab pack |
$4.95 |
$4.95 |
Postinor-1 |
1 October 2021 |
1 March 2022 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
DV limit |
Date of listing |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Levonorgestrel |
Tab 1.5 mg; 1 tab pack |
$4.95 |
$4.95 |
Postinor-1 |
1% |
1 October 2021 |
1 March 2022 |
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|
Aprepitant1 |
Cap 2 x 80 mg and 1 x 125 mg; 3 capsule OP blister pack |
$84.00 |
$30.00 |
Emend Tri-pack (Merck Sharp & Dohme (New Zealand) Limited) |
1 July 2021 |
1 December 2021 |
|
Brimonidine tartrate1 |
Eye drops 0.2%; 5 ml OP dropper bottle |
$12.25 |
$4.29 |
Arrow – Brimonidine (Teva Pharma New Zealand Ltd) |
1 August 2021 |
1 January 2022 |
|
Disulfiram1 |
Tab 200 mg; 100 tablet blister pack |
$250.00 |
$236.40 |
Antabuse (Teva Pharma New Zealand Ltd) |
1 June 2021 |
1 November 2021 |
1 This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender.
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Ibuprofen |
Tab long-acting 800 mg; 30 tablet blister pack |
$5.99 |
$3.05 |
Brufen SR (Mylan New Zealand Ltd) |
1 August 2021 |
1 January 2022 |
Ibuprofen SR BNM |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of subsidy change |
Principal Supply date |
|
|---|---|---|---|---|---|---|---|---|
|
Aprepitant2 |
Cap 2 x 80 mg and 1 x 125 mg; 3 blister pack |
$84.00 |
$30.00 |
Emend Tri-pack (Merck Sharp & Dohme (New Zealand) Limited) |
5% |
1 July 2021 |
1 December 2021 |
|
|
Brimonidine tartrate2 |
Eye drops 0.2%, 5 ml dropper bottle |
$12.25 |
$4.29 |
Arrow – Brimonidine (Teva Pharma New Zealand Ltd) |
5% |
1 August 2021 |
1 January 2022 |
|
|
Disulfiram2 |
Tab 200 mg; 100 tablet, blister pack |
$250.00 |
$236.40 |
Antabuse (Teva Pharma New Zealand Ltd) |
5% |
1 June 2021 |
1 November 2021 |
|
|
2 This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender. |
||||||||
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
DV limit |
Date of listing |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Ibuprofen |
Tab long-acting 800 mg; 30 tablet blister pack |
$5.99 |
$3.05 |
Brufen SR (Mylan New Zealand Ltd) |
5% |
1 August 2021 |
1 January 2022 |
Ibuprofen SR BNM |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
PHARMAC has resolved not to award tenders for Principal Supply Status for the following products listed in the 2020/21 Invitation to Tender, dated 2 November 2020
2020/21 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Amphotericin B |
Liposomal inj 50 mg |
|
Aprepitant (widened access) |
Cap 2 x 80 mg and 1 x 125 mg |
|
Benzbromarone |
Tab 25 - 100 mg |
|
Cidofovir |
Inj 75 mg per ml, 5 ml |
|
Ciprofloxacin |
Inj 2 mg per ml, 100 ml |
|
Diltiazem Hydrochloride |
Inj 5 mg per ml, 5 ml vial |
|
Diltiazem hydrochloride |
Tab 30 mg |
|
Diltiazem hydrochloride |
Tab 60 mg |
|
Doxorubicin |
Inj 10 mg |
|
Doxorubicin |
Inj 100 mg |
|
Doxorubicin |
Inj 50 mg |
|
Gentamicin sulphate |
Inj 10 mg per ml, 1 - 2 ml |
|
Gentamicin Sulphate |
Inj 40 mg per ml, 2 ml |
|
Glyceryl trinitrate |
Tab sublingual 600 mcg |
|
Haloperidol decanoate |
Inj 100 mg per ml, 1 ml |
|
Haloperidol decanoate |
Inj 50 mg per ml, 1 ml |
|
Hydrocortisone |
Oral liq |
|
Hydrocortisone |
Tab 1 mg |
|
Hydrocortisone |
Tab 20 mg |
|
Hydrocortisone |
Tab 4 mg |
|
Hydrocortisone |
Tab 5 mg |
|
Loperamide hydrochloride [split market] |
Tab 2 mg |
|
Metformin Hydrochloride |
Cap/tab sustained-release 1 g |
|
Metformin Hydrochloride |
Cap/tab sustained-release 500 mg |
|
Methadone hydrochloride |
Inj 10 mg per ml, 1 ml |
|
Metronidazole |
Gel 0.75% |
|
Morphine Hydrochloride |
Oral liq 1 mg per ml |
|
Morphine Hydrochloride |
Oral liq 10 mg per ml |
|
Morphine Hydrochloride |
Oral liq 2 mg per ml |
|
Morphine Hydrochloride |
Oral liq 5 mg per ml |
|
Nitrazepam |
Tab 5 mg |
|
Norfloxacin |
Tab 400 mg |
|
Pizotifen |
Tab 500 mcg |
|
Potassium citrate |
Tab |
|
Tenecteplase |
Inj 50 mg |
|
Terlipressin |
Inj 0.2 mg per ml, 10 ml |
|
Ziprasidone |
Cap 20 mg |
|
Ziprasidone |
Cap 40 mg |
|
Ziprasidone |
Cap 60 mg |
For products included in the 2018/19, 2019/20 or 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.